Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
16
Not yet recruiting, industry sponsors, Kidney and urology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed288
16 trials
Showing 1 to 16, recently updated first.
- Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary RetentionPivotal-lookingNot yet recruiting
Antev Ltd.Industry
NCT07733934 · 126 participants (planned) · Start Jan 2027 · Primary completion May 2028
Drug: Teverelix DP; Teverelix DP Placebo and 2 more · For: Acute Urinary Retention; Benign Prostate Hypertrophy(BPH)
- A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)Not yet recruiting
BiogenBiogen (BIIB)
NCT07889362 · 25 participants (planned) · Start Nov 16, 2026 · Primary completion Aug 13, 2028
Drug: Felzartamab · For: Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07861113 · 20 participants (planned) · Start Dec 15, 2026 · Primary completion Jun 15, 2028
Drug: Sibeprenlimab · For: Primary Membranous Nephropathy; Minimal Change Disease; Focal Segmental Glomerulosclerosis
- Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)Not yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07730632 · 60 participants (planned) · Start Aug 10, 2026 · Primary completion Aug 10, 2028
Drug: QLS7305 Injection · For: IgAN - IgA Nephropathy; Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN); C3 Glomerulopathy (C3G) and 1 more
Sites: Beijing, China
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney DiseasePivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07647133 · 249 participants (planned) · Start Jun 15, 2026 · Primary completion Oct 8, 2027
Drug: SAL0140 Tablets; SAL0140 Tablets and 1 more · For: Chronic Kidney Disease
Sites: Shenzhen, China; Nanjing, China
- SLN12140 in Adult Participants With IgA Nephropathy in ChinaNot yet recruiting
Linno Pharmaceuticals, Inc.Industry
NCT07553494 · 48 participants (planned) · Start May 29, 2026 · Primary completion Dec 2027
Drug: SLN12140 · For: IgA Nephropathy (IgAN)
Sites: Beijing, China
- A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney DiseasePivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07555054 · 182 participants (planned) · Start May 21, 2026 · Primary completion Nov 11, 2027
Drug: HS-10390; HS-10390 and 2 more · For: Chronic Kidney Disease
Sites: Guangzhou, China
- Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)Not yet recruiting
NovelMed TherapeuticsIndustry
NCT06454110 · 10 participants (planned) · Start Feb 2028 · Primary completion Dec 2030
Drug: NM8074 · For: IgA Nephropathy
- Efficacy and Safety Study of HS-10542 for IgA NephropathyNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07474636 · 90 participants (planned) · Start Mar 17, 2026 · Primary completion Dec 10, 2027
Drug: HS-10542 High Dose; HS-10542 Low Dose and 1 more · For: IgAN; Immunoglobulin A Nephropathy (IgAN); Glomerular Disease
Sites: Beijing, China
- Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.Not yet recruiting
Trigone Pharma Ltd.Industry
NCT07391878 · 60 participants (planned) · Start Feb 15, 2026 · Primary completion Dec 15, 2027
Drug: TRG-200 KIT · For: Overactive Bladder (OAB)
Sites: Jerusalem, Israel
- Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene TherapyNot yet recruiting
Cyllene TherapeuticsIndustry
NCT07227285 · 16 participants (planned) · Start Apr 2026 · Primary completion Apr 2031
Drug: EG110A · For: Urinary Bladder, Overactive; Spinal Cord Injury
Sites: Downey, California; Ann Arbor, Michigan; Philadelphia, Pennsylvania · 4 sites in all
- Study of CM313 in Subject With IgA NephropathyPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT06830395 · 106 participants (planned) · Start Sep 2025 · Primary completion Mar 2027
Drug: CM313; Placebo · For: IgA Nephropathy
Sites: Beijing, China
- Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease ProgressionPivotal-lookingNot yet recruiting
Ebima Clifford OkundayeIndustry
NCT06866236 · 3,000 participants (planned) · Start Oct 2025 · Primary completion Oct 2026
Drug: QRX-3 · For: Chronic Kidney Diseases; Acute Kidney Injury; Kidney Failure
Sites: Pasedena, Texas
- Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA NephropathyNot yet recruiting
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06982040 · 80 participants (planned) · Start May 2025 · Primary completion Sep 2026
Drug: NTQ5082 capsules 100 mg; NTQ5082 capsules 200 mg and 2 more · For: Primary IgA Nephropathy
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruiting
Sinocelltech Ltd.Industry
NCT06774664 · 99 participants (planned) · Start Jan 2025 · Primary completion Sep 2027
Drug: SCTC21C · For: IgA Nephropathy
Sites: Baotou, China; Beijing, China; Chengdu, China · 20 sites in all
- Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)Not yet recruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06687174 · 72 participants (planned) · Start Dec 31, 2024 · Primary completion Jun 15, 2026
Drug: MY008211A tablets; MY008211A tablets matched placebo · For: IgA Nephropathy (IgAN)
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.